• Ross Camidge, teaching

    CU docs work to boost minorities in (and leading) cancer trials

    Focus on training minority investigators By Todd Neff Clinical trials of cancer therapies are most…

  • Zhao09_52GA

    CU Cancer Center, MD Anderson awarded joint $4.25M grant to develop early-phase clinical trials

    The University of Colorado Cancer Center and The University of Texas MD Anderson Cancer Center…

  • BC.ribbon

    Study Highlights New Drug, Molecular Insight into Triple Negative Breast Cancers

    AACR 2014 study showcases a new drug active against triple-negative breast cancer, and through analysis of the drug’s mechanism of action, offers increased understanding of the biology of this very aggressive form of breast cancer.

  • Pills

    Phase II trial of efatutazone shows challenge of matching treatment to population

    AACR Research Results: While efatutazone did not improve the efficacy of erlotinib in this trial, researchers hope lessons from the trial will allow them to make better future use of the drug or other drugs in its class.

  • Gold

    Gold nanorods attach to, kill bladder cancer cells

    Bladder cancer cells overexpress the protein EGFR; gold nanorods can be engineered to attach to EGFR proteins; and then the application of low-intensity laser to the tissue can preferentially heat these gold nanorods, killing the EGFR-rich cancer cells to which they are attached.

In the Lab

BC.ribbon

Study Highlights New Drug, Molecular Insight into Triple Negative Breast Cancers

AACR 2014 study showcases a new drug active against triple-negative breast cancer, and through analysis of the drug’s mechanism of action, offers increased understanding of the biology of this very aggressive form of breast cancer.

Read the rest of this entry

In the Clinic

Meet the Experts

76868_10152129216354564_298078489_n

CU Cancer Center welcomes Darcey Sypolt, psychosocial oncology program coordinator

When Darcey Sypolt, MSW, LCSW,OSW-C is not in the Rockies biking, hiking or camping with…

Read the rest of this entry